The Trajectory of Epigenetic Chromatin Remodeling in Cardiometabolic Disease and its Therapeutic Implications

Abstract

The pathogenesis and progression of cardiometabolic diseases (CMD) are intricately linked to epigenetic regulation mediated by chromatin remodeling. Modifications to histones, such as post-translational acetylation and methylation, along with DNA methylation, alter chromatin structure and accessibility, resulting in transient or irreversible alterations in gene expression without accompanying changes in the DNA sequence. Herein, we outline the trajectory of epigenetic chromatin remodeling across various tissues, focusing on the liver-heart axis and the crosstalk between various epigenetic mechanisms in CMD pathogenesis and progression. We provide a list of drugs that target crucial epigenetic enzymes for CMD treatment. Furthermore, we propose possible future directions for the development of effective therapies targeting the crosstalk interaction points of epigenetic mechanisms involved in CMD.